- Stockwatch: biotech stock propagandists, beware!
- Post-Zohydro, Zogenix shifts focus to rare epilepsy, schizophrenia
- Naurex leads VC funding surge with $80 Series C
- Early Alzheimer's data sound good, but Biogen has much to prove
COMMENT Other Informa Comment
- The EMA at 20: CAT chair on where all the advanced therapies are, and Holoclar, the bright light of stem cell therapy
- PROFILE: Vas Narasimhan on many Novartis roles, extinction fears and Hilleman influences